Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: A 3-year follow-up study

Translational Psychiatry

Volumn 6, Issue , 2016, Pages

  Hashimoto, K ^a   Bruno, D ^b   Nierenberg, J ^c,d   Marmar, C R ^d   Zetterberg, H ^e,f   Blennow, K ^e   Pomara, N ^c,d  

^a CHIBA UNIVERSITY   (Japan)

^b LIVERPOOL HOPE UNIVERSITY   (United Kingdom)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GLUTAMIC ACID; GLUTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGED; AMINO ACID CEREBROSPINAL FLUID LEVEL; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; NERVE CELL; NEUROTRANSMISSION; AGING; COGNITION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SYNAPTIC TRANSMISSION;

AGED; AGING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; GLUTAMIC ACID; GLUTAMINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84959484796     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.8     Document Type: Article

References (47)

1. Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML. High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. Arch Gen Psychiatry 2010; 67: 489-496.
2. Diniz BS, Butters MA, Albert SM, Dew MA, Reynoilds CF. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013; 202: 329-335.
3. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530-538.
4. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012; 69: 493-498.
5. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009; 61: 105-123.
6. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013; 263: 367-377.
7. Hertz L. The glutamate-glutamine (GABA) cycle: importance of late postnatal development and potential reciprocal interactions between biosynthesis and degradation. Front Endocrinol (Lausanne) 2013; 4: 59.
8. Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 2014; 18: 1049-1063.
9. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426-437.
10. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010; 18: 293-303.
11. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013; 73: 1133-1141.
12. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015; 40: 259-267.
13. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310-1316.
14. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705-713.
15. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47: 305-313.
16. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64: 193-200.
17. Godlewska BR, Near J, Cowen PJ. Neurochemistry of major depression: a study using magnetic resonance spectroscopy. Psychopharmacology (Berl) 2015; 232: 501-507.
18. Hermens DF, Naismith SL, Chitty KM, Lee RS, Tickell A, Duffy SL et al. Cluster analysis reveals abnormal hippocampal neurometabolic profiles in young people with mood disorders. Eur Neuropsychopharmacol 2015; 25: 836-845.
19. Arnone D, Mumuni AN, Jauhar S, Condon B, Cavanagh J. Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: meta-analysis of absolute prefrontal neuro-metabolic concentrations. Eur Neuropsychopharmacol 2015; 25: 1109-1117.
20. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000; 47: 586-593.
21. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2007; 61: 162-166.
22. Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J Affect Disord 2013; 146: 262-265.
23. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naïve schizophrenic patients. BMC Psychiatry 2005; 5: 6.
24. Hashimoto K. Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brain. Schizophr Res 2014; 156: 281-282.
25. Pålsson E, Jakobsson J, Södersten K, Fujita Y, Sellgren C, Ekman CJ et al. Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur Neuropsychopharmacol 2015; 25: 133-140.
26. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012; 169: 523-530.
27. Buschke H. Retrieval in human learning. Trans N Y Acad Sci 1974; 36: 721-729.
28. Army Individual Test Battery Manual of Directions and Scoring. Adjutant General's Office, War Department: Washington, DC, USA, 1994.
29. Goodglass H, Kaplan E. Assessment of Aphasia and Related Disorders. Lea & Febiger: Philadelphia, PA, USA, 1972.
30. Fukushima T, Kawai J, Imai K, Toyo'oka T. Simultaneous determination of D-and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed Chromatogr 2004; 18: 813-819.
31. Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry 2014; 171: 1320-1327.
32. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653-15658.
33. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009; 4: e6585.
34. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006; 6: 3414-3425.
35. Miguel-Hidalgo JJ, Waltzer R, Whittom AA, Austin MC, Rajkowska G, Stockmeier CA. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord 2010; 127: 230-240.
36. Bernstein HG, Meyer-Lotz G, Dobrowolny H, Bannier J, Steiner J, Walter M et al. Reduced density of glutamine synthetase immunoreactive astrocytes in different cortical areas in major depression but not in bipolar I disorder. Front Cell Neurosci 2015; 9: 273.
37. Bielau H, Steiner J, Mawrin C, Trübner K, Brisch R, Meyer-Lotz G et al. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann N Y Acad Sci 2007; 1096: 157-169.
38. Karolewicz B, Maciag D, O'Dwyer G, Stockmeier CA, Feyissa AM, Rajkowska G. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol 2010; 13: 411-420.
39. Smith CC, Bowen DM, Francis PT, Snowden JS, Neary D. Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 1985; 48: 469-471.
40. Csernansky JG, Bardgett ME, Sheline YI, Morris JC, Olney JW. CSF excitatory amino acids and severity of illness in Alzheimer's disease. Neurology 1996; 46: 1715-1720.
41. Pomara N, Singh R, Deptula D, Chou JCY, Schwartz MB, LeWitt PA. Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry 1992; 149: 251-254.
42. Gunnersen D, Haley B. Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker. Proc Natl Acad Sci USA 1992; 89: 11949-11953.
43. Tumani H, Shen G, Peter JB, Brück W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? Arch Neurol 1999; 56: 1241-1245.
44. Timmer NM, Herbert MK, Claassen JA, Kuiperij HB, Verbeek MM. Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. Neurobiol Aging 2015; 36: 1271-1273.
45. Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 2015; 10.1038/mp.2015.83; e-pub ahead of print 18 August 2015.
46. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res 2011; 191: 122-127.
47. Taylor MJ, Tiangga ER, Mhuircheartaigh RN, Cowen PJ. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol 2012; 26: 733-737.